Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3571 | Ultra Brief Online Mindfulness-based Intervention Wiki | 0.71 |
| drug2431 | Passed infection of SARS-CoV-2 Wiki | 0.71 |
| drug881 | Control Wiki | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006330 | Heart Defects, Congenital NIH | 1.00 |
| D018376 | Cardiovascular Abnormalities NIH | 0.71 |
| D009205 | Myocarditis NIH | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012819 | Myocarditis HPO | 0.25 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.13 |
Navigate: Correlations HPO
There are 2 clinical trials
The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection, are elderly patients (> 70 years), obese patients, patients with chronic renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease), high blood pressure, diabetes, and cancer. The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients. CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today. The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population. This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France
Description: Prevalence of Covid-19 infection in the overall CHD population
Measure: Prevalence of Covid-19 infection in the overall CHD population Time: through study completion, an average of 2 weeksDescription: Prevalence of Covid-19 infection per CHD sub-group
Measure: Prevalence of Covid-19 infection per CHD sub-group Time: through study completion, an average of 2 weeksDescription: Cardiovascular complications
Measure: Cardiovascular complications Time: through study completion, an average of 2 weeksDescription: Other complications
Measure: Other complications Time: through study completion, an average of 2 weeksDescription: Number of deaths
Measure: Number of deaths Time: through study completion, an average of 2 weeksThe study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.
Description: Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance
Measure: Myocarditis Time: up to 3 monthsDescription: Prevalence of pericarditis assessed by clinical criteria
Measure: Pericarditis Time: up to 3 monthsDescription: Prevalence of atrial fibrillation on EKG
Measure: Atrial fibrillation Time: up to 3 monthsDescription: Prevalence of ischemic heart disease assessed by cardiac magnetic resonance
Measure: Ischemic heart disease Time: up to 3 monthsDescription: Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance
Measure: Dilatation of right heart chambers Time: up to 3 monthsDescription: Prevalence of valvular heart disease assessed by cardiac magnetic resonance
Measure: Valvular hear disease Time: up to 3 monthsDescription: Prevalence of prolonged QT interval on EKG
Measure: Rhythm disorders Time: up to 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports